Clovis Oncology, Inc. (NASDAQ:CLVS) – Stock analysts at Leerink Swann issued their Q2 2017 earnings estimates for shares of Clovis Oncology in a research note issued on Monday. Leerink Swann analyst M. Schmidt expects that the biopharmaceutical company will earn ($1.30) per share for the quarter. Leerink Swann has a “Outperform” rating and a $85.00 price objective on the stock. Leerink Swann also issued estimates for Clovis Oncology’s Q3 2017 earnings at ($1.21) EPS, Q4 2017 earnings at ($1.12) EPS, FY2017 earnings at ($4.95) EPS, FY2018 earnings at ($3.79) EPS, FY2019 earnings at ($2.17) EPS, FY2020 earnings at $0.16 EPS and FY2021 earnings at $3.16 EPS.
Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.43) by $0.10. The business had revenue of $7.05 million for the quarter, compared to the consensus estimate of $6.04 million.
Several other analysts have also recently weighed in on the company. Credit Suisse Group reissued an “outperform” rating and set a $88.00 price objective (up from $74.00) on shares of Clovis Oncology in a report on Friday. ValuEngine raised Clovis Oncology from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. J P Morgan Chase & Co set a $72.00 price objective on Clovis Oncology and gave the stock a “buy” rating in a report on Thursday, June 1st. Bank of America Corporation reissued a “buy” rating and set a $75.00 price objective on shares of Clovis Oncology in a report on Wednesday, May 17th. Finally, Morgan Stanley reissued an “overweight” rating and set a $79.00 price objective on shares of Clovis Oncology in a report on Tuesday, May 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $63.33.
Clovis Oncology (NASDAQ:CLVS) opened at 59.97 on Thursday. The company’s market cap is $2.68 billion. The stock’s 50 day moving average is $54.46 and its 200 day moving average is $55.14. Clovis Oncology has a 52-week low of $11.57 and a 52-week high of $74.94.
Several institutional investors have recently bought and sold shares of CLVS. FMR LLC raised its position in Clovis Oncology by 271.4% in the first quarter. FMR LLC now owns 1,816,859 shares of the biopharmaceutical company’s stock valued at $115,679,000 after buying an additional 1,327,703 shares during the last quarter. Wellington Management Group LLP raised its position in Clovis Oncology by 10,143.6% in the first quarter. Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company’s stock valued at $84,788,000 after buying an additional 1,318,669 shares during the last quarter. State Street Corp raised its position in Clovis Oncology by 93.7% in the fourth quarter. State Street Corp now owns 2,141,663 shares of the biopharmaceutical company’s stock valued at $95,131,000 after buying an additional 1,035,917 shares during the last quarter. Alliancebernstein L.P. raised its position in Clovis Oncology by 1,538.0% in the first quarter. Alliancebernstein L.P. now owns 754,122 shares of the biopharmaceutical company’s stock valued at $48,015,000 after buying an additional 708,082 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Clovis Oncology by 25.3% in the first quarter. Vanguard Group Inc. now owns 3,285,195 shares of the biopharmaceutical company’s stock valued at $209,169,000 after buying an additional 662,969 shares during the last quarter. Institutional investors own 97.55% of the company’s stock.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $61.82, for a total transaction of $185,460.00. Following the completion of the transaction, the insider now directly owns 200,583 shares in the company, valued at approximately $12,400,041.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 9,000 shares of company stock valued at $495,690 over the last 90 days. Corporate insiders own 17.40% of the company’s stock.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/brokers-offer-predictions-for-clovis-oncology-inc-s-q2-2017-earnings-clvs/1916873.html
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.